Business
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations
SOUTH SAN FRANCISCO, Calif., July 9, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif., July 9, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the promotions of Paul A. Stone, J.D., as Chief Financial Officer, Andres Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A., as Vice President, Development Operations. \n\n \nPaul previously served as Senior Vice President, General Counsel and Head of Operations. As Chief Financial Officer, he will lead the finance, investor relations, and public relations functions, and will continue as the Principal Financial and Accounting Officer. Paul will also continue to oversee the legal function as General Counsel. Prior to joining IDEAYA, Paul was with 5AM Ventures in various capacities including as Partner, General Counsel, and Chief Operating Officer, and held early management and operating roles in companies launched at 5AM Ventures, including IDEAYA Biosciences (NASDAQ: IDYA), Homology Medicines, Cidara Therapeutics, and Entrada Therapeutics. Paul earlier served in management roles at Ethos Pharmaceuticals, Ilypsa (acquired by Amgen), and Symyx Technologies. \n\"Paul brings a unique combination of financial, investment, business development, and legal experience into the role of Chief Financial Officer at IDEAYA Biosciences. He is a proven biotechnology executive, and has been instrumental in executing on several key milestones for IDEAYA, including the license of Phase 1/2 PKC inhibitor IDE196 from Novartis, and our initial public offering on NASDAQ,\" said Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences.\nIn other leadership highlights, IDEAYA announced the following promotions:\nAndres Ruiz Briseno, C.P.A., has been promoted to Vice President, Finance. Andres most recently served as Senior Director, Finance, and Controller, and has been a key contributor to finance and operational activities of the company. Andres previously was Associate Director of Financial Planning and Analysis at Pharmacyclics, where he helped lead the organization's finance and operations efforts in support of the successful launch of IMBRUVICA® (ibrutinib) through its acquisition by AbbVie, and earlier held roles at Theravance and PricewaterhouseCoopers. \nMick O'Quigle...